Cytoskeletal proteins play important roles in regulating cellular morphology, cytokinesis and intracellular signaling. In this report, we describe a developmentally regulated gene encoding a novel cell lineage-restricted cytoskeletal protein, designated SM22b. SM22b shares high-grade sequence identity with the smooth muscle cell (SMC)-specific protein, SM22a, the neuron-specific protein, NP25, and the Drosophila melanogaster flight muscle-specific protein, mp20. The mouse SM22b cDNA encodes a 199-amino acid polypeptide that contains a single conserved calponin-like repeat domain. During mouse embryonic development, the SM22b gene is expressed in a temporally and spatially regulated pattern in the tunica media of arteries and veins, endocardium and compact layer of the myocardium, bronchial epithelium and mesenchyme of the lung, gastrointestinal epithelium and cartilaginous primordia. During postnatal development, SM22b is co-expressed with SM22a in arterial and venous SMCs. In addition, SM22b is expressed at high levels in the bronchial epithelium and lung mesenchyme, gastrointestinal epithelial cells and in the cartilagenous and periosteal layer of bones. Three-dimensional deconvolution microscopic analyses of A7r5 SMCs revealed that SM22b co-localizes with SM22a to cytoskeletal actin filaments. Taken together, these data demonstrate that SM22b is a novel actin-associated protein with a unique cell lineage-restricted pattern of expression. q
Results
SM22a encodes a cytoskeletal protein that is an early developmental marker of the smooth muscle cell (SMC) lineage expressed exclusively in SMCs during postnatal development (Chiavegato et al., 1999; Li et al., 1996; Shapland et al., 1993; Zhang et al., 2001 ). Mice harboring a targeted mutation in the SM22a gene exhibit no obvious defects in the histology or ultrastructure of SMC-containing tissues, arteries and veins suggesting that another, as yet unidentified, gene product may be co-expressed with SM22a in SMCs (Zhang et al., 2001) . Consistent with this hypothesis, a BLASTN search of GenBank revealed six overlapping expressed sequence tags (ESTs) that demonstrated high-grade sequence identity to SM22a. This novel cDNA, designated SM22b, was cloned from a mouse heart cDNA library (see Section 2). The mouse SM22b cDNA (GenBank Accession Number AF465519) encodes a 199-amino acid polypeptide with a predicted molecular mass of 22.4 kDa. ClustalW analyses revealed that the SM22b protein is 68% sequence identical to the mouse SM22a protein, 73% identical to the human neuron-specific protein, NP-25 (Ren et al., 1994) and 37% identical to the Drosophila muscle-specific protein, mp20 (Ayme-Southgate et al., 1989) . A point to be noted is each protein contains a calponin-like repeat (CLR) domain (gray box, Fig. 1 ) and a potential EF hand (Kretsinger, 1980) calcium-binding domain (boxed, Fig. 1 ). Moreover, each of these proteins co-localizes to actin filaments (Small and Gimona, 1998) .
To determine the tissue-and cell lineage-restricted pattern of SM22b gene expression, Northern blot analyses were performed. A single 1.35 kb signal was observed in multiple tissues including the heart, aorta, stomach, small intestine, uterus, lung and kidney ( Fig. 2A , lanes 1-6 and www.elsevier.com/locate/modo 11). Low levels of SM22b mRNA were also observed in the spleen, thymus, brain and kidney ( Fig. 2A, lanes 7-9) . In contrast, SM22a mRNA was observed exclusively in SMCrich tissues including the aorta, small intestine, lung and uterus, but not in the spleen, thymus and kidney (Solway et al., 1995) .
To examine the cell lineage-restricted pattern of SM22b, the radiolabeled SM22b cDNA probe was hybridized to a Northern blot containing RNA harvested from SMC and non-SMC lineages. As anticipated, SM22b mRNA was observed in primary rat aortic SMCs and A7r5 cells which were derived from the embryonic rat thoracic aorta. Surprisingly, SM22b mRNA was also observed in RNA harvested from NIH 3T3 cells, C2C12 skeletal myoblasts and myotubes, EL-4 T cells, WEHI B cells and adult and embryonic cardiac myocytes (Fig. 2B, lanes 4-12) . In contrast, SM22b was not detected in mRNA harvested from MG-63 osteoblast cells, Caco-2 adenocarcinoma cells and H441 lung carcinoma cells (Fig. 2B, lanes 1-3) . These data demonstrate that SM22b is expressed in a unique cell lineage-restricted pattern that differs markedly from the muscle-restricted pattern of the SM22a gene (Solway et al., 1995) .
To determine the temporal and spatial pattern of SM22b gene expression during embryonic development, in situ hybridization analyses were performed on staged CD-1 mouse embryos. As shown in this transverse section through the primitive heart tube of an embryonic day (E)8.0 mouse embryo, SM22b is expressed (white signal) in the endocardium (E), but not in the ventricular myocardium (Vn) (Fig. Fig. 1 (Small and Gimona, 1998 3A). In addition, the SM22b gene is expressed diffusely in the cells surrounding the pharyngeal region of the foregut diverticulum (P) and dorsal aorta (Ao). In E9.5 embryos, as shown in sagittal ( Fig. 3B ) and transverse ( Fig. 3C ) sections, SM22b is expressed in the endocardium (E), the branchial arch arteries (Br), the paraxial and somitic (So) mesoderm, the dorsal aortae (Ao) and veins including the anterior cardinal (ACV) and vitelline. Subsequently, at E14.5, as shown in this sagittal section, the SM22b gene is expressed throughout the lung (Lu), the gastrointestinal epithelium (GI), in cartilaginous primordia of the vertebral bodies (V) and in the endocardium as well as the compact layer of the ventricular myocardium (H) (Fig. 3E,F) . In addition, a few expressing cells are observed in the liver (Li) . Finally, by late gestation (E19.5), as shown in these sagittal sections ( Fig. 3G-I ), intense hybridization of the SM22b cRNA probe is observed throughout the lung (Lu, Fig. 3G ), the gastrointestinal epithelium (GI, Fig. 3G ) and skeletal structures including the vertebral bodies (V, Fig. 3F ,G), digits (D, Fig. 3H ) and the sternebrae (St, Fig. 3G ). Within the heart, SM22b is expressed in the endocardium and heart valves (HV, Fig. 3G ) and at a low, but detectable, level in the myocardium. SM22b gene expression is also detected in the great arteries (A, Fig. 3G ) and veins. Of note, the SM22b gene is not expressed in the SMC-containing muscularis mucosa in the gastrointestinal tract (Fig. 3I ). This pattern of gene expression differs markedly from the SM22a gene which is expressed in vascular and visceral SMCs and transiently in the myotomal component of the somites and the primitive heart (Li et al., 1996) .
To determine whether the pattern of SM22b gene and protein expression correlate and to characterize the pattern of SM22b expression in the adult mouse, sections from E18.5 and 8-week old CD-1 mice were harvested, fixed and stained with affinity-purified rabbit polyclonal antisera raised against the recombinant mouse SM22b (see Section 2). Consistent with the pattern of SM22b gene expression observed at late gestation (Fig. 3F-I ), in E18.5 embryos, intense immunostaining (white color) is observed throughout the lung (Fig. 4A) , in the stomach and intestinal epithelium (Epi, Fig. 4B ,C) and in skeletal structures including the vertebral bodies (V, Fig. 4D ). In addition, SM22b protein is detectable in arteries, veins and the heart (not shown). In 8-week old CD-1 mice, SM22b is expressed in a patchy, focal pattern throughout the media of large arteries including the aorta (Ao, Fig. 4E ), and in a more diffuse pattern in the tunica media of veins including the superior vena cava (SVC, Fig. 3F ) and smaller arteries including the coronary arteries (Cor, Fig. 4G ). In addition, intense immunostaining of gastrointestinal epithelium of the esophagus (Epi, Fig.  4H ), stomach and intestine is observed. Once again, immunostaining of the muscularis mucosa of the gastrointestinal tract is not observed (Mus, Fig. 4H ). Consistent with its pattern of gene expression in the embryo, SM22b is expressed in cartilage and periosteum covering bones including the distal phalanges (Ph, Fig. 4I ) and throughout the lung (data not shown).
To determine the subcellular localization of SM22b in SMCs, deconvolution microscopic analyses were performed. High-resolution images of A7r5 SMCs expressing an enhanced green fluorescent protein (EGFP)-SM22b fusion protein revealed that the EGFP-SM22b localized to the cytoskeletal actin filaments (Fig. 5B,C) . To determine whether SM22a and SM22b co-localize, SMCs were cotransfected with expression plasmids encoding DsRedSM22a and EGFP-SM22b. Overlaying of the FITC channel, which detects the EGFP-SM22b protein (panel 5E), with the rhodamine channel, which detects DsRed-SM22a protein (panel 5D), revealed that both SM22a and SM22b localize to actin filaments in these SMCs (Fig. 5F ). Taken together, these data demonstrate that SM22b encodes a novel celllineage-restricted cytoskeletal protein with a unique developmentally regulated pattern of expression.
Materials and methods

Isolation and characterization of murine SM22b cDNA clones
A BLASTN search of the GenBank database with the 603 bp coding region of the mouse SM22a cDNA (GenBank Accession No. P37804) revealed six overlapping mouse ESTs (AA221584, AA107410, AA409743, AA220512, AA389017, AA144457) that share high-level nucleotide sequence identity to SM22a. To clone this cDNA, that we designated SM22b, reverse transcriptase-polymerase chain reaction (RT-PCR) was performed using total mouse uterine RNA and the XhoI-linked PCR primer corresponding to bp 275-301 of EST AA221584 (5 0 -CACCTCGAGCTCTG GGAAGGAAAGAACATGGCTTGT-3 0 ) and the EcoRIlinked oligo-dT primer (5 0 -CACAAGCTTTTTTTTTTTT-TTTTTTTTT-3 0 ) as described previously (Parmacek and Leiden, 1991) . The resulting 1.0 kb mouse SM22b cDNA fragment (corresponding to bp 398-1341 in Fig. 1 ) was subcloned into pBluescript II KS. To identify a full length SM22b cDNA clone, the 1.0 kB mouse SM22b cDNA fragment (bp 398-1341) was used to screen a BALB/c mouse heart cDNA library (Clontech) as described previously (Parmacek and Leiden, 1991) . Five cDNA clones were isolated, the longest of which were 1341 bp in length. These SM22b cDNA clones were subcloned into EcoRI/ XhoI-digested pBluescript II KS (Stratagene) to generate the plasmid, designated pSM22b-BS. To confirm that the SM22b cDNA clones isolated from the cardiac cDNA library were full-length, 5 0 -rapid amplification of cDNA ends (RACE) and S1 nuclease analyses were performed as described previously (Solway et al., 1995) . 5 0 -RACE was performed using the Marathone cDNA Amplification Kit (Clontech) with the antisense primer (5 0 -TAGGAAACCAGTTGGGAT-3 0 ) corresponding to bp 492-509 in Fig. 1 and a second antisense primer (5 0 -CAGGTTCATTAGTGTCCG-3 0 ) corresponding to bp 431-448 in Fig. 1 . 5 0 -RACE products obtained with each antisense primer were subcloned into the pBluescriptII KS and their nucleotide sequences determined as described previously (Solway et al., 1995) . The transcriptional start site was confirmed by S1 nuclease protection analyses using a radiolabeled synthetic oligonucleotide probe corresponding to mouse SM22b genomic subfragment consisting of the immediate 5 0 flanking region of the SM22b gene and the 5 0 untranslated region of the mouse SM22b cDNA (bp 1-21, in Fig. 1 ) as described previously (Samaha et al., 1996) . Following incubation with S1 nuclease, the expected 21 bp product was observed (data not shown).
Plasmids
As described above, pSM22b-BS encodes the full-length mouse SM22b cDNA (bp 1-1341) subcloned into pBluescriptII KS (Stratagene). The pDsRed1-SM22a expression plasmid encoding the DsRed1 protein (Clontech) fused inframe to the mouse SM22a protein (aa 1-201) was generated by subcloning the mouse SM22a cDNA into EcoRI/XhoIdigested pDsRed1-C1(Clontech). The pEGFP-SM22b expression plasmid encoding the EGFP fused in-frame to the mouse SM22b protein (aa 1-199) was generated by subcloning the mouse SM22b cDNA (bp 53-652) into EcoRI/XhoI-digested pEGFP-C1 (Clontech). The pGEXSM22b expression vector encoding the glutathione-S-transferase (GST)-tagged mouse SM22b fusion protein, was generated by subcloning the mouse SM22b cDNA (bp 53-652) into EcoRI/XhoI-digested pGEX-4T-1 (Amersham Pharmacia).
Cell culture and transfections
Primary rat aortic smooth muscle cells (VSMCs) were isolated and grown in culture as described previously (Chang et al., 1995) . A7r5 cells, derived from the thoracic aorta of the embryonic rat were grown as described previously (Solway et al., 1995) . MG-63 cells, a transformed human osteoblast cell line, Caco-2 cells, a human colorectal adenocarcinoma cell line, H441 cells, a human lung epithelial cell line, NIH 3T3 fibroblasts, C2C12 skeletal myoblasts and myotubes, EL4 mouse T cells, and WEHI mouse B cells were grown as described previously (Parmacek et al., 1990) .
Northern blot and in situ hybridization analyses
Northern blot analyses were performed using the radiolabeled 1.3 kb mouse SM22b cDNA probe as described previously (Parmacek and Leiden, 1989) and RNA harvested from CD-1 mice. In situ hybridization of staged murine embryos were performed as described previously . The SM22b-BS plasmid was linearized with BamHI (antisense) and EcoRI (sense), and labeled with T7 (sense) or T3 (antisense) DNA polymerase in the presence of 35 S-labeled dUTP to generate antisense and control sense cRNA probes.
Preparation of SM22b polyclonal antiserum
The pGEX-SM22b plasmid was transformed into bacteria and GST tagged-SM22b fusion protein was induced and purified from bacterial extracts as described previously (Morrisey et al., 1997) . Rabbits were immunized with the purified fusion protein as per standard protocol of the Cocalico Biologicals, Inc. (Reamstown, PA). Preimmune and immune IgG were isolated from the serum by protein ASepharose chromatography as described previously (Zhang et al., 2001) . Cross-reactivity against SM22a and GST was eliminated by affinity chromatography through GSTSM22a and GST affinity columns, respectively.
Immunohistochemistry and deconvolution microscopy
For immunohistochemical localization studies, E18.5 CD-1 mouse embryos and tissues from 8-week-old CD-1 mice were fixed and sections incubated with either the affinitypurified SM22b IgG primary antibody or control rabbit preimmune IgG as described previously (Zhang et al., 2001) . Sections were then incubated with FITC-labeled goat anti-rabbit secondary antibody at a dilution between 1:100 and 1:250 and visualized on a Zeiss Axiophot microscope. For the subcellular localization studies, A7r5 cells transfected with the pDsRed1-SM22a and pEGFP-SM22b plasmids, were fixed in 3.7% formalin, permeabilized with 0.2% Triton-X100, and incubated with either rhodaminephalloidin (Cytoskeleton, Inc., for EGFP-SM22b) or FITCphalloidin (Sigma, for DsRed1-SM22a) as described previously (Zhang et al., 2001) . To determine whether SM22a and/or SM22b co-localize, A7r5 SMCs were cotransfected with the pDsRED1-SM22a and pEGFPSM22b expression plasmids. Wide-field fluorescence optical sections were acquired using a DeltaVision microscopy system (Applied Precision, Issaquah, WA) consisting of a mercury arc illumination source, a Zeiss 63 £ /1.4NA Plan Apochromat objective lens, a cooled CCD camera (Princeton Instruments, Trenton, NJ), and appropriate barrier filter sets (Chroma, Brattleboro, VT) for EGFP (l ex ¼ 490 nm, l em ¼ 528 nm) and DsRed1 (l ex ¼ 555 nm, l em ¼ 617 nm). Image restoration and volume projections were computed using SoftWoRx software (Applied Precision), as previously described (Helmke et al., 2000) .
